CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
乳腺癌脑膜转移当前治疗模式的综合综述
英文原题：A comprehensive review of current treatment modalities for leptomeningeal carcinomatosis in breast cancer.
查看英文原题
A comprehensive review of current treatment modalities for leptomeningeal carcinomatosis in breast cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
软脑膜癌病（LC）是乳腺癌的一种转移性并发症，可导致患者预后极差并出现令人痛苦的神经系统症状。虽然随着癌症患者生存率的提高，LC 的发病率有所上升，但目前仍没有既定的 LC 治疗方案，且比较现有疗法的临床试验数据有限。本文对 pubmed 和 Cochrane 数据库进行了全面的文献检索。总结了目前针对乳腺癌 LC 的治疗方式及其安全性/有效性特征。讨论了新兴疗法在 LC 中的作用，包括靶向药物、CAR-T、免疫检查点抑制剂、CDK 抑制剂和新型抗体偶联药物。还提出了一条 LC 的治疗路径，以指导临床医生管理这一严重的乳腺癌转移性并发症。
展开英文摘要原文
Leptomeningeal carcinomatosis (LC) is a metastatic complication of breast cancer that imparts a very poor prognosis and distressing neurologic symptoms in affected patients. While the incidence of LC has risen with improving survival rates for cancer patients, there remains no established treatment protocol for LC and clinical trial data comparing available therapies is limited.
Here, a comprehensive literature search of the pubmed and Cochrane databases was performed. Current treatment modalities and their safety/ efficacy profiles are summarized for LC in breast cancer. Roles for emerging therapies in LC are discussed, including targeted agents, CAR-T, immune checkpoint inhibitors, CDK inhibitors and novel antibody conjugates. A treatment pathway for LC is also proposed to guide clinicians through management of this severe metastatic complication of breast cancer.
论文信息
- 作者
- Morris CD、Humphrey C、Dillon P
- 第一作者单位
- Emily Couric Comprehensive Cancer Center, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, USA.United States
- 通讯作者单位
- Emily Couric Comprehensive Cancer Center, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, USA. Electronic address: pmd5b@uvahealth.org.United States
- 文献类型
- 综述
- 期刊
- Critical reviews in oncology/hematology2024 Dec
- 原文标识
- PubMed 39278427 · DOI 10.1016/j.critrevonc.2024.104513